Baseline patient and disease characteristics
| . | Total (N = 206) . | Insurance status . | Neighborhood opportunity∗ . | ||||
|---|---|---|---|---|---|---|---|
| Private insurance (N = 132) . | Medicaid (N = 74) . | P . | High COI (N = 151) . | Low COI (N = 50) . | P . | ||
| Age categories, n (%) | .170 | .070 | |||||
| <5 y | 23 (11.2) | 15 (11.4) | 8 (10.8) | 19 (12.6) | 3 (6.0) | ||
| 5-9.99 y | 57 (27.7) | 30 (22.7) | 27 (36.5) | 35 (23.2) | 19 (38.0) | ||
| 10 to 17.99 y | 89 (43.2) | 63 (47.7) | 26 (35.1) | 65 (43.0) | 23 (46.0) | ||
| ≥18 | 37 (18.0) | 24 (18.2) | 13 (17.6) | 32 (21.2) | 5 (10.0) | ||
| Sex, n (%) | .770 | .620 | |||||
| Male | 120 (58.3) | 78 (59.1) | 42 (56.8) | 91 (60.3) | 28 (56.0) | ||
| Female | 86 (41.7) | 54 (40.9) | 32 (43.2) | 60 (39.7) | 22 (44.0) | ||
| Race and ethnicity, n (%) | <.001 | <.001 | |||||
| White non-Hispanic | 131 (63.6) | 101 (76.5) | 30 (40.5) | 109 (72.2) | 18 (36.0) | ||
| Black or African American | 15 (7.3) | 6 (4.5) | 9 (12.2) | 10 (6.6) | 5 (10.0) | ||
| Hispanic | 44 (21.4) | 13 (9.8) | 31 (41.9) | 20 (13.2) | 23 (46.0) | ||
| Other | 16 (7.8) | 12 (9.1) | 4 (5.4) | 12 (7.9) | 4 (8.0) | ||
| Cytogenetics category, n (%)† | .560 | .800 | |||||
| Favorable | 42 (20.4) | 29 (22.0) | 13 (17.6) | 34 (22.5) | 8 (16.0) | ||
| Intermediate risk | 24 (11.7) | 14 (10.6) | 10 (13.5) | 15 (9.9) | 7 (14.0) | ||
| High risk | 63 (30.6) | 37 (28.0) | 26 (35.1) | 45 (29.8) | 17 (34.0) | ||
| Uninformative | 71 (34.5) | 49 (37.1) | 22 (29.7) | 52 (34.4) | 17 (34.0) | ||
| Missing | 6 (2.9) | 3 (2.3) | 3 (4.1) | 5 (3.3) | 1 (2.0) | ||
| Disease status at referral, n (%) | .026 | .740 | |||||
| Primary refractory | 33 (16.0) | 28 (21.2) | 5 (6.8) | 25 (16.6) | 8 (16.0) | ||
| First relapse | 62 (30.1) | 35 (26.5) | 27 (36.5) | 47 (31.1) | 13 (26.0) | ||
| Second relapse | 77 (37.4) | 50 (37.9) | 27 (36.5) | 53 (35.1) | 22 (44.0) | ||
| Third or greater relapse | 34 (16.5) | 19 (14.4) | 15 (20.3) | 26 (17.2) | 7 (14.0) | ||
| Marrow status preinfusion, n (%) | .010 | .049 | |||||
| <0.01% | 76 (36.9) | 38 (28.8) | 38 (51.4) | 49 (32.5) | 26 (52.0) | ||
| 0.01% to 4.99% | 42 (20.4) | 33 (25.0) | 9 (12.2) | 35 (23.2) | 6 (12.0) | ||
| 5% to 24.99% | 16 (7.8) | 11 (8.3) | 5 (6.8) | 11 (7.3) | 5 (10.0) | ||
| >25% | 72 (35.0) | 50 (37.9) | 22 (29.7) | 56 (37.1) | 13 (26.0) | ||
| Previous HSCT | 88 (42.7%) | 53 (40.2%) | 35 (47.3%) | .380 | 63 (41.7%) | 23 (46.0%) | .620 |
| Previous radiation | 112 (54.37) | 69 (52.27) | 43 (58.11) | .467 | 79 (52.32) | 31 (62.00) | .255 |
| Previous blinatumomab | 25 (12.1%) | 17 (12.9%) | 8 (10.8%) | .820 | 17 (11.3%) | 7 (14.0%) | .620 |
| Previous inotuzumab | 17 (8.3%) | 14 (10.6%) | 3 (4.1%) | .120 | 14 (9.3%) | 3 (6.0%) | .570 |
| CAR T-cell product, n (%) | .001 | .660 | |||||
| CTL019 (trial) | 128 (62.1) | 83 (62.9) | 45 (60.8) | 95 (62.9) | 29 (58.0) | ||
| huCART19 (trial) | 33 (16.0) | 13 (9.8) | 20 (27.0) | 22 (14.6) | 10 (20.0) | ||
| Kymriah (commercial) | 45 (21.8) | 36 (27.3) | 9 (12.2) | 34 (22.5) | 11 (22.0) | ||
| Clinical trial or commercial | .008 | .555 | |||||
| Clinical trial | 161 (78.2%) | 96 (72.7) | 65 (87.8) | 117 (77.5%) | 39 (78.0%) | ||
| Commercial product | 45 (21.8%) | 36 (27.3) | 9 (12.2) | 34 (22.5%) | 11 (22.0%) | ||
| Year of infusion, n (%) | .520 | .830 | |||||
| 2012 and 2013 | 22 (10.7) | 18 (13.6) | 4 (5.4) | 19 (12.6) | 3 (6.0) | ||
| 2014 | 23 (11.2) | 13 (9.8) | 10 (13.5) | 17 (11.3) | 5 (10.0) | ||
| 2015 | 25 (12.1) | 17 (12.9) | 8 (10.8) | 18 (11.9) | 7 (14.0) | ||
| 2016 | 31 (15.0) | 19 (14.4) | 12 (16.2) | 23 (15.2) | 6 (12.0) | ||
| 2017 | 51 (24.8) | 29 (22.0) | 22 (29.7) | 36 (23.8) | 13 (26.0) | ||
| 2018 | 38 (18.4) | 25 (18.9) | 13 (17.6) | 26 (17.2) | 12 (24.0) | ||
| 2019 and 2020 | 16 (7.8) | 11 (8.3) | 5 (6.8) | 12 (7.9) | 4 (8.0) | ||
| . | Total (N = 206) . | Insurance status . | Neighborhood opportunity∗ . | ||||
|---|---|---|---|---|---|---|---|
| Private insurance (N = 132) . | Medicaid (N = 74) . | P . | High COI (N = 151) . | Low COI (N = 50) . | P . | ||
| Age categories, n (%) | .170 | .070 | |||||
| <5 y | 23 (11.2) | 15 (11.4) | 8 (10.8) | 19 (12.6) | 3 (6.0) | ||
| 5-9.99 y | 57 (27.7) | 30 (22.7) | 27 (36.5) | 35 (23.2) | 19 (38.0) | ||
| 10 to 17.99 y | 89 (43.2) | 63 (47.7) | 26 (35.1) | 65 (43.0) | 23 (46.0) | ||
| ≥18 | 37 (18.0) | 24 (18.2) | 13 (17.6) | 32 (21.2) | 5 (10.0) | ||
| Sex, n (%) | .770 | .620 | |||||
| Male | 120 (58.3) | 78 (59.1) | 42 (56.8) | 91 (60.3) | 28 (56.0) | ||
| Female | 86 (41.7) | 54 (40.9) | 32 (43.2) | 60 (39.7) | 22 (44.0) | ||
| Race and ethnicity, n (%) | <.001 | <.001 | |||||
| White non-Hispanic | 131 (63.6) | 101 (76.5) | 30 (40.5) | 109 (72.2) | 18 (36.0) | ||
| Black or African American | 15 (7.3) | 6 (4.5) | 9 (12.2) | 10 (6.6) | 5 (10.0) | ||
| Hispanic | 44 (21.4) | 13 (9.8) | 31 (41.9) | 20 (13.2) | 23 (46.0) | ||
| Other | 16 (7.8) | 12 (9.1) | 4 (5.4) | 12 (7.9) | 4 (8.0) | ||
| Cytogenetics category, n (%)† | .560 | .800 | |||||
| Favorable | 42 (20.4) | 29 (22.0) | 13 (17.6) | 34 (22.5) | 8 (16.0) | ||
| Intermediate risk | 24 (11.7) | 14 (10.6) | 10 (13.5) | 15 (9.9) | 7 (14.0) | ||
| High risk | 63 (30.6) | 37 (28.0) | 26 (35.1) | 45 (29.8) | 17 (34.0) | ||
| Uninformative | 71 (34.5) | 49 (37.1) | 22 (29.7) | 52 (34.4) | 17 (34.0) | ||
| Missing | 6 (2.9) | 3 (2.3) | 3 (4.1) | 5 (3.3) | 1 (2.0) | ||
| Disease status at referral, n (%) | .026 | .740 | |||||
| Primary refractory | 33 (16.0) | 28 (21.2) | 5 (6.8) | 25 (16.6) | 8 (16.0) | ||
| First relapse | 62 (30.1) | 35 (26.5) | 27 (36.5) | 47 (31.1) | 13 (26.0) | ||
| Second relapse | 77 (37.4) | 50 (37.9) | 27 (36.5) | 53 (35.1) | 22 (44.0) | ||
| Third or greater relapse | 34 (16.5) | 19 (14.4) | 15 (20.3) | 26 (17.2) | 7 (14.0) | ||
| Marrow status preinfusion, n (%) | .010 | .049 | |||||
| <0.01% | 76 (36.9) | 38 (28.8) | 38 (51.4) | 49 (32.5) | 26 (52.0) | ||
| 0.01% to 4.99% | 42 (20.4) | 33 (25.0) | 9 (12.2) | 35 (23.2) | 6 (12.0) | ||
| 5% to 24.99% | 16 (7.8) | 11 (8.3) | 5 (6.8) | 11 (7.3) | 5 (10.0) | ||
| >25% | 72 (35.0) | 50 (37.9) | 22 (29.7) | 56 (37.1) | 13 (26.0) | ||
| Previous HSCT | 88 (42.7%) | 53 (40.2%) | 35 (47.3%) | .380 | 63 (41.7%) | 23 (46.0%) | .620 |
| Previous radiation | 112 (54.37) | 69 (52.27) | 43 (58.11) | .467 | 79 (52.32) | 31 (62.00) | .255 |
| Previous blinatumomab | 25 (12.1%) | 17 (12.9%) | 8 (10.8%) | .820 | 17 (11.3%) | 7 (14.0%) | .620 |
| Previous inotuzumab | 17 (8.3%) | 14 (10.6%) | 3 (4.1%) | .120 | 14 (9.3%) | 3 (6.0%) | .570 |
| CAR T-cell product, n (%) | .001 | .660 | |||||
| CTL019 (trial) | 128 (62.1) | 83 (62.9) | 45 (60.8) | 95 (62.9) | 29 (58.0) | ||
| huCART19 (trial) | 33 (16.0) | 13 (9.8) | 20 (27.0) | 22 (14.6) | 10 (20.0) | ||
| Kymriah (commercial) | 45 (21.8) | 36 (27.3) | 9 (12.2) | 34 (22.5) | 11 (22.0) | ||
| Clinical trial or commercial | .008 | .555 | |||||
| Clinical trial | 161 (78.2%) | 96 (72.7) | 65 (87.8) | 117 (77.5%) | 39 (78.0%) | ||
| Commercial product | 45 (21.8%) | 36 (27.3) | 9 (12.2) | 34 (22.5%) | 11 (22.0%) | ||
| Year of infusion, n (%) | .520 | .830 | |||||
| 2012 and 2013 | 22 (10.7) | 18 (13.6) | 4 (5.4) | 19 (12.6) | 3 (6.0) | ||
| 2014 | 23 (11.2) | 13 (9.8) | 10 (13.5) | 17 (11.3) | 5 (10.0) | ||
| 2015 | 25 (12.1) | 17 (12.9) | 8 (10.8) | 18 (11.9) | 7 (14.0) | ||
| 2016 | 31 (15.0) | 19 (14.4) | 12 (16.2) | 23 (15.2) | 6 (12.0) | ||
| 2017 | 51 (24.8) | 29 (22.0) | 22 (29.7) | 36 (23.8) | 13 (26.0) | ||
| 2018 | 38 (18.4) | 25 (18.9) | 13 (17.6) | 26 (17.2) | 12 (24.0) | ||
| 2019 and 2020 | 16 (7.8) | 11 (8.3) | 5 (6.8) | 12 (7.9) | 4 (8.0) | ||
Five patients had addresses that could not be geocoded, thus removed in all COI analyses.
High-risk lesions defined as KMT2A (MLL) rearrangements, Philadelphia-chromosome, Ph-like, hypodiploid (<44 chromosomes), and TCF3/HLF fusion. Intermediate-risk lesions included iAMP21, IKZF1 deletion, or TCF3/PBX1. Favorable cytogenetics were defined as the presence of hyperdiploidy (>51 chromosomes), or ETV6/RUNX1 fusion. Any other lesions not specified were considered uninformative based on prior analysis of cytogenetics and CAR T-cell therapy outcomes.